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Abstract
Background: Association studies have identified low penetrance alleles that participate to the risk of cancer development.
The 8q24 chromosomal region contains several such loci involved in various cancers that have been recently studied for
their propensity to influence the clinical outcome of prostate cancer. We investigated here two 8q24 breast and colon
cancer risk alleles in the close vicinity of the MYC gene for their role in the occurrence of distant metastases.
Methodology/Principal findings: A retrospective series of 449 patients affected with breast or colon adenocarcinoma was
genotyped for the rs13281615 and/or rs6983267 SNPs. Statistical analyses were done using the survival package v2.30 in the
R software v2.9.1. The two SNPs did not influence the development of distant metastases of colon cancer; rs6983267
showed a mild effect on breast cancer. However, this effect was greatly emphasized when considering inflammatory breast
cancer (IBC) solely. Replicated on a larger and independent series of IBC the contribution of the genotype to the metastatic
risk of IBC was found an independent predictor of outcome (p=2e-4; OR 8.3, CI95:2.6–33).
Conclusions/Significance: Our study shows first that the monitoring of this specific germline variation may add a substantial
tool for IBC prognostication, an aggressive disease that evolves towards distant metastases much more frequently than
non-IBC and for which no reliable prognostic factor is available in medical practice. Second, it more generally suggests that
risk alleles, while associated with low susceptibility, could correlate with a high risk of metastasis.
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Introduction
The number of treatment options available to patients with
breast or colorectal cancer has greatly increased due to a better
understanding of cancer biology. Multigene assays have added to
the ability to predict disease outcome and degree of response to
adjuvant chemotherapy. However a significant proportion of
patients with early-stage cancer will develop unpredicted meta-
static disease. Candidate genes approaches have identified
functional polymorphisms in MMP, PAI-1, HIF-1-alpha, caspases
or ACE that moderately influence the risk of invasiveness or
metastasis of several cancers, such as those of colon, prostate or
lung. More recently, the contribution of cancer susceptibility
alleles to clinical outcome has also been evaluated. In prostate
cancer patients, an increased frequency of metastasis has been
found associated with SNPs genotypes that also increase the risk
for cancer itself [1]. These observations indicate that the host
genetic constitution may not only contribute to the initial risk of
primary tumor development but also to the subsequent risk of
metastasis.
Association studies have identified multiple cancer susceptibility
loci in a one-megabase region upstream of the MYC promoter.
Risk alleles have been found for some of the most frequent human
carcinomas, prostate, colon and breast, but also for other types
such as ovary or bladder [2–3]. Several studies have explored the
implication of MYC in the molecular mechanism underlying this
susceptibility. It is a well known target of the WNT signaling
pathway that is activated in multiple cancer types, including colon,
breast and prostate carcinomas [4–6]. The transcription factor
TCF7L2/TCF4 has been reported to bind to the rs6983267
region in an allele-specific manner, suggesting that this risk locus
may act as part of a cis-regulatory enhancer element for MYC [7–
8]. Close to rs6983267 that has been reported to modulate
colorectal cancer risk, an independent SNP rs13281615 has been
linked to breast cancer risk.
We report here the allelic frequencies of both rs13281615 and
rs6983267 in patients affected with colorectal or breast cancer and
their behavior according to the disease evolution and the
morphologic features of these two cancer types.
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Genotypes and Metastatic Risk of Colon and Breast
Cancers
The two 8q24 rs13281615 and rs6983267 SNPs were
genotyped in the learning series of 152 colon cancers (Table S1)
and 207 breast cancers (Table S2). The frequencies of different
alleles were similar to those described in the litterature (Table 1).
To analyze the contribution of the risk allele (G allele) to the
metastatic process, patients with at least one G allele were
compared to those homozygous for the non-risk allele. Search for
correlations between the two categories of genotypes at both loci
(Gx vs. AA or TT) and the 5-year metastasis-free survival (MFS)
failed to reveal difference in outcome among the two groups of
colon cancers patients (Figure 1A-B). For breast cancers, MFS was
not associated with genotype at the rs13281615 locus (Figure 1C).
However, the risk allele of the rs6983267 locus was weakly
associated with an increase in metastatic risk. At 5 years, the
metastatic-free survival was 85% (95% CI 74–97) for patients with
the TT genotype vs. 68% (95% CI 61–76) for those with the Gx
genotype (p,0.02, log-rank test, Figure 1D). Separate analysis of
IBC and non-IBC patients did not reveal any difference in survival
for non-IBC patients (5-year MFS of 82% vs. 76%, p=0.38, log-
rank test, Figure 1E). However, when the analysis was restricted to
IBC patients a striking difference in MFS was observed: the TT
genotype was associated with a 5-year MFS of 100% (95% CI
100–100) whereas the Gx genotype was associated with a 5-year
MFS of 41% (95% CI 27–63) (p=0.005, log-rank test; Figure 1F).
To validate the MFS association observed with the rs6983267
locus in this first series of 42 IBC, an independent series of 90 IBC
samples was analyzed using the same experimental approach. As
shown in Figure 2A, the 5-year MFS of IBC patients displayed
a similar pattern, with 79% (95% CI 60–100) for patients of TT
genotype and 41% (95%CI 31–55) for those bearing at least one G
allele (p=0.0113, log-rank test). The two IBC series were then
merged into a single one (Table S3). Regarding the rs6983267
SNP, 25 patients were of TT genotype (19%) and 107 of Gx
genotype (81%). Correlations of genotypes and histo-clinical
factors were assessed (Table S4). Genotype was not associated
with any of the histo-clinical factors (age, histological type and
grade, estrogen receptor (ER), progesterone receptor (PR) and
ERBB2 status, pathological response to chemotherapy) but with
MFS: 66 of the 107 Gx patients (62%) displayed metastatic relapse
vs only 4 of the 25 (16%) TT patients (p=3.8E-05, Fisher’s exact
test). The 5-year MFS was 41% in the case of a Gx genotype vs.
86% in the case of a TT genotype (p=0.0002, log-rank test;
Figure 2B). Within the 107 Gx patients, those of GG (38 cases)
and those of GT (69 cases) genotype did have a similar behavior
(Figure 2C).
Prognostic Value of Rs6983267 SNP in Inflammatory
Breast Cancer
Univariate and multivariate analyses of the MFS were then
done to compare the prognostic performance of the rs6983267
genotype with that of histo-clinical factors in IBC (Table S5). In
univariate analysis, the hazard ratio (HR) for metastatic relapse
was 5.56 when comparing Gx to TT genotypes (95% CI [2.00–
14.3], p=0.0009). The PR status was also associated with MFS,
whereas ER and ERBB2 status and the pathological response only
tended to be associated with the outcome. Information regarding
the three variables showing significance with a p-value lower than
0.1 in univariate analysis (i.e. genotype, PR and ER status) was
available for 130 of the 132 samples thus making possible
a multivariate analysis. In the latter, PR status lost its prognostic
significance and ER remained not significant. Only the rs6983267
genotype remained significant.
Gene Expression and Genome Profiles in IBC According
to the Rs6983267 Genotype
We next wanted to determine whether differences in genotype
could be associated with specific characteristics. We searched for
differences in RNA expression profiles in IBC samples classified
according to their rs6983267 genotype (Gx vs. TT) or their
metachronous metastatic status (presence or absence) using
a previously published data set (GEO accession number
GSE23720); no significant difference was found; in particular,
a difference in MYC mRNA expression was not detected.
Similarly, array-based comparative genomic hybridization failed
to detect specific genomic profiles [9–10]; again, no difference in
amplification level of the 8q24 region around MYC was observed
and thus, no candidate gene emerged at this stage. However it had
previously been shown that the control of MYC expression was
subtle when studying the possible influence of the genotype on
MYC expression level [7,8,11–13].
Discussion
This association study globally showed that the two independent
SNPs, rs13281615 and rs6983267, which modulate the risk of
breast and colorectal cancer respectively, have no major influence
on the development of distant metastases in colon cancer.
However, it unexpectedly revealed that the rs6983267 genotype
strongly influences the metastatic risk of an aggressive form of
breast cancer, namely inflammatory breast cancer. Because the
metastatic risk was found comparable for patients of GT and GG
Table 1. Genotyping data at loci rs13281615 and rs6983267 in the learning and the merged IBC series.
SNP Genotype Colon cancers
1 Breast cancers
1 Inflammatory breast cancers
2
GG 47 (31%) 55 (26%) 38 (29%)
rs6983267 GT 68 (45%) 107 (52%) 69 (52%)
TT 37 (24%) 45 (22%) 25 (19%)
rs13281615 AA 43 (31%) 48 (25%) 10 (25%)
AG 72 (52%) 104 (54%) 22 (55%)
GG 24 (17%) 39 (21%) 8 (20%)
1learning sets;
2merged learning and validation sets.
doi:10.1371/journal.pone.0037943.t001
Inherited Metastatic Risk in Breast Cancer
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e37943Figure 1. Kaplan-Meier analysis of metastasis-free survival in colon cancers and breast cancers for rs13281615 and rs6983267
genotypes. Comparison of MFS curves for patients with at least one risk allele (Gx) and no risk alleles (AA for rs13281615; TT for rs6983267): in colon
cancers at rs13281615 (part A) and at rs6983267 (part B) SNPs; in breast cancers at rs13281615 (part C) and at rs6983267 (part D) SNPs; in non-IBCs
(part E), and in IBCs (part F) at rs6983267.
doi:10.1371/journal.pone.0037943.g001
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allele. The absence of the G allele reduced the metastatic risk to
a level similar to that of non-IBCs patients. The presence of the G
allele in a context of inflammatory tumor might thus potentiate
a specific metastatic mechanism that would superimpose to the
« standard » metastatic risk of breast cancer. With an odd ratio of
8.3 (CI95: 2.6–33), the prognostic value of the G allele might add
to the predictive value derived from the currently limited pre-
therapeutic evaluation of IBC patients. It might be interesting to
use this feature in prospective studies. For instance, the monitoring
of the rs6983267 genotype of IBC patients would enable to focus
the analysis on subgroups of patients with comparable risk for
metastasis. Because genotypic studies can be done retrospectively,
this approach might not only be applicable to future studies but
also to past surveys.
The alleles of rs6983267 are known to differentially bind
transcription regulating elements such TCF7L2/TCF4 [12–13].
The downstream activation of corresponding snpRNAs have also
been involved in the phenotypic orientation of prostate cancer
[14]. We found the presence of a large chromatin-loop bringing
the rs6983267 in the vicinity of MYC in two IBC cell lines
SUM149 and SUM190 (unpublished observations done in
collaboration with Matthew Freedman) suggesting that the
increased metastatic risk of inflammatory tumors might be
promoted by a deregulation of the MYC gene, as it was initially
proposed for colon cancer [4]. Because IBC is defined by the
presence of tumor emboli within dermal lymphatic vessels and as it
was recently shown that vessels inflammation could be regulated
by beta-catenin-independent signaling pathway involving WNT5A
and TNF alpha signaling [15], IBC specificity could be linked to
WNT/TCF4/MYC pathway activation in inflammatory lym-
phatic vessels.
In conclusion, the rs6983267(G) allele, initially described as
a low penetrance susceptibility locus for colorectal and prostate
cancers, appears to be associated with a high risk for metastasis in
inflammatory breast cancer. The implementation of new tools for
tumor prognostication, presently based on the histo-clinical factors
and somatic mutations, may benefit from the monitoring of
specific germline variations of the IBC patients. To date, no
candidate gene emerges from expression studies, but MYC remains
a good one as it is able to binds both alleles of rs6983267 through
a large chromatin-loop in two IBC cell lines. Further functional
studies have thus to delineate this physical link. Although IBC do
not exhibit a specific expression profile, they tend to aggregate
poor prognosis breast cancer clusters, being commonly of basal-
like subtype, showing Her-2 amplification, EGFR overexpression
and lacking estrogen and progesterone receptors. Variations in the
NFKB1 and COX2 genes expression linked to HER-2 and EGFR
expression levels might be interesting arguments to propose
targeted therapies [16]. Finally, other known cancer risk loci could
be associated with metastatic risk in subgroups of cancer and new
association studies may identify more susceptibility loci to
metastasis.
Materials and Methods
Ethic Statement
All patients signed a written informed consent and the study was
approved by our institutional review board.
Biological Material
Tumor tissue samples were collected from 359 patients with
invasive adenocarcinomas, who underwent surgical biopsies or
initial surgery at the Institut Paoli-Calmettes. Patients were
generally native from the Mediterranean basin mainly including
North-Africa and Italy. These samples constituted the learning
series including breast and colon cancers selected from the Data
Management Centre of Institut Paoli-Calmettes (Marseille,
France). Selection criteria included the availability of a pre-
treatment genomic DNA sample, no distant metastasis at diagnosis
and long-term follow-up (Tables S1 and S2).
Additional samples were collected from patients affected with
inflammatory breast cancer (IBC) to validate the results observed
in the learning set. IBC presented with diffuse erythema,
associated with a local sensation of heat and edema, induration
and the typical ‘‘peau d’orange’’ aspect of the skin. Skin biopsies
that were systematically performed at diagnosis objectived the
blockage of lympahtic channels due to tumor emboli [16]. A total
of 76 new samples from IBC patients, non-metastatic at diagnosis,
were retained from the IBC database of Institut Paoli-Calmettes,
because of the availability of fixed tissue sample in the
Biopathology department. Because IBC is a rare disease that
contributes for less than 5% of breast cancer fourteen non-
metastatic cases collected from patients treated at the Antwerp
University Hospital (Belgium) were also recruited to enlarge the
series, leading to a validation series of 90 IBC cases. None of these
Figure 2. Kaplan-Meier analysis of metastasis-free survival in IBCs for rs6983267. Parts A and B. Comparison of MFS curves for IBC patients
with at least one risk allele (Gx) and no risk alleles (TT) at rs6983267 in the validation set (part A) and in the pooled learning and validation sets (part
B). Part C. Comparison of MFS curves for all IBC patients with at least one risk allele (Gx) according to the genotype GG vs. GT.
doi:10.1371/journal.pone.0037943.g002
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represents one of the largest series of IBC ever constituted. The
characteristics of all IBC from both learning and validation series
are presented in additional table 3.
Genotyping
Genomic DNA was extracted from either frozen or formalin-
embedded fixed material using the DNA QIAampH micro-kit as
recommended by the manufacturer. The quality and quantity of
extracted DNA were evaluated with a NanoDrop ND-1000
spectrophotometer (Thermo Fisher Scientific, Illkirch France).
The rs13281615 and rs6983267 loci were double-strand se-
quenced after two rounds of PCR amplification using the
59GGACCGTAGCTTCTGTATCTGCAA/59 AGTGTCTT-
TATGGCCCTAGCAG and 59TCCTATCTCAGCTCCC-
TATCCA/59 CCCAATCCTGAGAAACTTGC pairs of primers
at 58uC and 55uC for annealing, respectively. To validate
genotypic data derived from fixed material, IBC samples from
the learning series were also characterized on fixed material. No
discordance was noticed.
Statistical Analyses
Correlations between sample groups and histo-clinical factors
were calculated with the Fisher’s exact test for qualitative variables
with discrete categories. Follow-up was measured from the date of
diagnosis to the date of last news for patients without any
metastatic relapse. Metastasis-free survival (MFS) was calculated
from the date of diagnosis until the date of first distant relapse
using the Kaplan-Meier method. Survival was compared between
groups with the log-rank test. Univariate and multivariate analyses
were done using Cox regression analyses. The p-values were based
on the Wald test and patients with one or more missing data were
excluded. All statistical tests were two-sided at the 5% level of
significance. Analyses were done using the survival package
(version 2.30) in the R software (version 2.9.1).
Supporting Information
Table S1 Histo-clinical characteristics of the colon
cancer series. 1, rectal cancers were excluded. After colonic
surgery, patients were treated according to standard guidelines;
54% received adjuvant 5-fluoro-uracil-based chemotherapy. The
median follow-up of patients without any metastatic relapse was 58
months after diagnosis. A total of 37 patients experienced
a metastatic relapse. The 5-year metastasis-free survival (MFS)
was 74% (95%CI 67–82).
(DOC)
Table S2 Histo-clinical characteristics of the breast
cancer series. 1, The breast samples were obtained from
surgical biopsies or initial surgery. Positive immunohistochemical
(IHC) status for ER and PR was defined by 10% or more stained
tumor cells; ERBB2-positive status was defined as 3+score using
the DAKO HercepTest, or 2+score complemented with Fluores-
cent In Situ Hybridisation (FISH) amplification (HER2/CEP17
ratio higher than 2.2). Due to a specific referral to our institution,
the 207 cases comprised 42 inflammatory breast cancers (IBC)
defined upon clinical criteria as T4d tumors and 165 non-
inflammatory breast cancers (non-IBCs). Patients were treated
according to standard guidelines: 99% of patients had surgery and
99% received adjuvant radiotherapy. All patients received
adjuvant and/or neo-adjuvant chemotherapy and 50% received
adjuvant hormone therapy. The median follow-up of patients with
no metastatic relapse was 80 months after diagnosis. A total of 66
patients experienced a metastatic relapse. The 5-year MFS was
72% (95%CI 66–79); 2, IDC, invasive ductal cancer; ILC, invasive
lobular cancer; IBC, inflammatory breast cancer; 3, concerns non-
IBC only.
(DOC)
Table S3 Histo-clinic characteristics of the merged IBC
series. 1, All patients were treated with primary chemotherapy
and most of them with surgery and radiotherapy. After
completion, adjuvant hormone therapy was given to 58% of
them. With a median follow-up of 72 months after diagnosis, the
5-year MFS was 50% (95% CI 41–59); 2, IDC, invasive ductal
cancer; ILC, invasive lobular cancer.
(DOC)
Table S4 rs6983267 genotyping and histo-clinical corre-
lations in the merged series of IBC.
(DOC)
Table S5 Uni- and multivariate logistic regression
analyses for MFS in the merged IBC series.
(DOC)
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